Fusion Pharmaceuticals Inc. Operating Income
Fusion Pharmaceuticals Inc. reported Operating Income of -$35.86 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2024-05-07
- Fusion Pharmaceuticals Inc. operating income (loss) for the quarter ending 2024-03-31 was -$35.86M.
- Fusion Pharmaceuticals Inc. operating income (loss) for the quarter ending 2023-12-31 was -$28.27M.
- Fusion Pharmaceuticals Inc. operating income (loss) for the quarter ending 2023-09-30 was -$19.39M.
- Fusion Pharmaceuticals Inc. operating income (loss) for the quarter ending 2023-06-30 was -$26.71M.
- Fusion Pharmaceuticals Inc. operating income (loss) for fiscal 2023 was -$99.23M.
- Fusion Pharmaceuticals Inc. operating income (loss) for fiscal 2022 was -$88.03M.
- Fusion Pharmaceuticals Inc. operating income (loss) for fiscal 2021 was -$82.02M.
- Fusion Pharmaceuticals Inc. operating income (loss) for fiscal 2020 was -$37.94M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$35.86M 10-Q · filed 2024-05-07 | -$64.14M derived: sum of 2 quarters · filed 2024-05-07 | -$83.52M derived: sum of 3 quarters · filed 2024-05-07 | -$110.24M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | -$28.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$47.66M derived: sum of 2 quarters · filed 2024-03-20 | -$74.38M derived: sum of 3 quarters · filed 2024-03-20 | -$99.23M 10-K · filed 2024-03-20 |
| 2023-09-30 | -$19.39M 10-Q · filed 2023-11-07 | -$46.10M derived: sum of 2 quarters · filed 2023-11-07 | -$70.96M 10-Q · filed 2023-11-07 | -$95.37M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | -$26.71M 10-Q · filed 2023-08-08 | -$51.57M 10-Q · filed 2023-08-08 | -$75.98M derived: sum of 3 quarters · filed 2024-05-07 | -$99.79M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | -$24.86M 10-Q · filed 2024-05-07 | -$49.27M derived: sum of 2 quarters · filed 2024-05-07 | -$73.08M derived: sum of 3 quarters · filed 2024-05-07 | -$92.36M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$24.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$48.22M derived: sum of 2 quarters · filed 2024-03-20 | -$67.51M derived: sum of 3 quarters · filed 2024-03-20 | -$88.03M 10-K · filed 2024-03-20 |
| 2022-09-30 | -$23.80M 10-Q · filed 2023-11-07 | -$43.09M derived: sum of 2 quarters · filed 2023-11-07 | -$63.62M 10-Q · filed 2023-11-07 | -$81.17M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$19.29M 10-Q · filed 2023-08-08 | -$39.81M 10-Q · filed 2023-08-08 | -$57.37M derived: sum of 3 quarters · filed 2023-08-08 | -$76.88M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$20.52M 10-Q · filed 2023-05-11 | -$38.08M derived: sum of 2 quarters · filed 2023-05-11 | -$57.59M derived: sum of 3 quarters · filed 2023-05-11 | -$84.86M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$17.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$37.07M derived: sum of 2 quarters · filed 2023-03-16 | -$64.33M derived: sum of 3 quarters · filed 2023-03-16 | -$82.02M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$19.52M 10-Q · filed 2022-11-08 | -$46.78M derived: sum of 2 quarters · filed 2022-11-08 | -$64.46M 10-Q · filed 2022-11-08 | -$76.06M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$27.27M 10-Q · filed 2022-08-09 | -$44.95M 10-Q · filed 2022-08-09 | -$56.55M derived: sum of 3 quarters · filed 2022-08-09 | -$66.86M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$17.68M 10-Q · filed 2022-05-10 | -$29.28M derived: sum of 2 quarters · filed 2022-05-10 | -$39.60M derived: sum of 3 quarters · filed 2022-05-10 | -$46.91M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$21.92M derived: sum of 2 quarters · filed 2022-03-17 | -$29.23M derived: sum of 3 quarters · filed 2022-03-17 | -$37.94M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$10.32M 10-Q · filed 2021-11-09 | -$17.63M derived: sum of 2 quarters · filed 2021-11-09 | -$26.34M 10-Q · filed 2021-11-09 | -$32.48M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$7.31M 10-Q · filed 2021-08-10 | -$16.02M 10-Q · filed 2021-08-10 | -$22.16M derived: sum of 3 quarters · filed 2021-08-10 | -$26.32M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$8.70M 10-Q · filed 2021-05-11 | -$14.84M derived: sum of 2 quarters · filed 2021-05-11 | -$19.00M derived: sum of 3 quarters · filed 2021-05-11 | -$22.91M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | -$6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$10.30M derived: sum of 2 quarters · filed 2021-03-25 | -$14.21M derived: sum of 3 quarters · filed 2021-03-25 | -$18.22M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$4.16M 10-Q · filed 2020-11-10 | -$8.07M derived: sum of 2 quarters · filed 2020-11-10 | -$12.08M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$3.91M 10-Q · filed 2020-08-11 | -$7.92M 10-Q · filed 2020-08-11 |